Pathstone Family Office’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Pathstone Family Office’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-35	Closed	-$2K	–	1009
2020 Q1	$2K	Buy	+35	New	+$3.15K	﹤0.01%	701
2019 Q2	–	Sell	-40	Closed	-$4K	–	942
2019 Q1	$4K	Hold	40	–	–	﹤0.01%	661
2018 Q4	$4K	Buy	+40	New	+$4.15K	﹤0.01%	407

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Pathstone Family Office's ICPT Position: Q2 2020 in Review

Pathstone Family Office sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2020, closing a stake of 35 shares — an estimated $2K sold.

Pathstone Family Office first reported a position in ICPT in Q4 2018 and held it in 3 quarters. The position peaked at $4K in Q1 2019. 192 funds tracked by Wall St. Rank hold ICPT as of Q2 2020.

Pathstone Family Office reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
Pathstone Family Office sold 35 Intercept Pharmaceuticals, Inc. shares in Q2 2020, an estimated $2K.
Pathstone Family Office first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2018 and held it in 3 quarters.
Pathstone Family Office's Intercept Pharmaceuticals, Inc. position peaked at $4K in Q1 2019.
192 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2020.

Based on Pathstone Family Office's 13F filing for Q2 2020, filed 14 Aug 2020.